Featured News

Wheeler Bio and MindImmune Therapeutics Sign CDMO Partnership Agreement to Support MindImmune's Lead Alzheimer's Prevention Program, MITI-101

September 17, 2025

Read the Press Release

Wheeler Bio and MindImmune Therapeutics Sign CDMO Partnership Agreement to Support MindImmune's Lead Alzheimer's Prevention Program, MITI-101

September 17, 2025

Read the Press Release

MindImmune Awarded Grant to Accelerate IND-Enabling Studies through Rhode Island Life Science Hub

June 1, 2025

MindImmune Therapeutics today announced it has been awarded a grant by Rhode Island Life Science Hub to accelerate the company’s preclinical development...
Read the Press Release

MindImmune Awarded Grant to Accelerate IND-Enabling Studies through Rhode Island Life Science Hub

June 1, 2025

MindImmune Therapeutics today announced it has been awarded a grant by Rhode Island Life Science Hub to accelerate the company’s preclinical development...
Read the Press Release

MindImmune Appoints Thomas Prod’homme, Ph.D., as Vice President, Preclinical Development

April 17, 2025

Accomplished immunologist brings 15 years of experience in preclinical development, translational biology and drug discovery
Read the Press Release

MindImmune Appoints Thomas Prod’homme, Ph.D., as Vice President, Preclinical Development

April 17, 2025

Accomplished immunologist brings 15 years of experience in preclinical development, translational biology and drug discovery
Read the Press Release

MindImmune Therapeutics Announces $12.4 million Series A Financing

June 13, 2022

Investors participating in the round include Dolby Family Ventures, Pfizer Ventures, the Alzheimer’s Drug Discovery Foundation (ADDF), Trend Venture, RightHill Ventures (an affiliate of the Slater Technology Fund) and several private investors.
Read the Press Release

MindImmune Therapeutics Announces $12.4 million Series A Financing

June 13, 2022

Investors participating in the round include Dolby Family Ventures, Pfizer Ventures, the Alzheimer’s Drug Discovery Foundation (ADDF), Trend Venture, RightHill Ventures (an affiliate of the Slater Technology Fund) and several private investors.
Read the Press Release

Other News

Passing of Dr. Mike Poole

November 1, 2024

MindImmune Therapeutics Appoints Brad Margus and Robert Michael Poole, MD FACP, to its Board of Directors

January 3, 2024

Providence Business News

Five Questions With: Stevin Zorn

July 26, 2022

Convergence RI

Nipping Alzheimer’s disease in the blood

June 27, 2022

Slater Technology Fund

RightHill Ventures Commits $1.5 Million to Slater-Backed Drug Discovery Company

June 21, 2022

Alzheimer’s Drug Discovery Foundation

Measurement of immune cell recruitment as a biomarker of neuroinflammation in Alzheimer’s disease and other diseases of the central nervous system

January 1, 2022

Press Release

MindImmune Therapeutics to Conduct Research on Specialized Immune Cells with Pfizer, Inc.

January 22, 2018

Slater Technology Fund

Slater Fund Closes on Second Round of Funding

August 21, 2017